Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.25
Bid: 42.50
Ask: 44.00
Change: 3.00 (7.32%)
Spread: 1.50 (3.529%)
Open: 42.25
High: 44.00
Low: 44.00
Prev. Close: 41.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Dec 2015 16:44

RNS Number : 6368H
Avacta Group PLC
01 December 2015
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Avacta Group plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Revised Transparency Directive

X

3. Full name of person(s) subject to thenotification obligation: iii

Henderson Group plc

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

26 November 2015

6. Date on which issuer notified:

30 November 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

Above 12%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

831,621,060

831,621,060

825,370,108

12.23%

GB0033519546

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

828,970,108

12.29%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

See Annex 1 below.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Revised Transparency Directive notification.

 

This disclosure has been calculated based on total voting rights outstanding amount 6,743,645,954.

14. Contact name:

HGIThresholdDisclosures@henderson.com

15. Contact telephone number:

020 7818 5738 / 4184

 

Annex 1: Information in relation to the person subject to the notification obligation (please tick the applicable box):

 

[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii

 

[X] Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, Alphagen Capital Limited

Below 5%

0

Below 5%

Henderson Group plc, Henderson Group Holdings Asset Management Limited, HGI Asset Management Group Limited, Henderson Global Group Limited, Henderson Holdings Group Limited, HGI Group Limited, Henderson Global Investors (Holdings) Limited, Henderson Global Investors

7.61%

0

7.61%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDMMGZVMMGKZM
Date   Source Headline
10th Oct 20187:00 amRNSAvacta agrees Affimer reagent licensing deal
2nd Oct 20187:00 amRNSPreliminary Results
21st Sep 20187:00 amRNSInvestor Meeting and Presentation
5th Sep 20187:15 amEQSHardman & Co Research: Avacta (AVCT): Capital increase for further development
5th Sep 20187:00 amRNSNotice of Results
31st Aug 20189:55 amRNSHolding(s) in Company
23rd Aug 20185:07 pmRNSHolding(s) in Company
23rd Aug 20185:06 pmRNSHolding(s) in Company
23rd Aug 201811:21 amRNSHolding(s) in Company
22nd Aug 20182:23 pmRNSHolding(s) in Company
22nd Aug 20189:20 amRNSHolding(s) in Company
17th Aug 201811:30 amRNSResult of General Meeting
6th Aug 20184:24 pmRNSHolding(s) in Company
30th Jul 20186:06 pmRNSResults of Placing and Subscription
30th Jul 201811:41 amRNSProposed Placing and Subscription to raise £11.4m
30th Jul 201810:35 amEQSHardman & Co Research: Avacta (AVCT): Ground-breaking new drug conjugate platform
24th Jul 20187:00 amRNSMajor Therapeutics Co-development Partnership
26th Jun 20181:30 pmEQSHardman & Co Research: Avacta (AVCT): Gearing up the management team
11th Jun 20187:00 amRNSAppointment of Non-Executive Chairman
31st May 201812:15 pmEQSHardman & Co Research: Avacta (AVCT): In vivo expression of Affimers
22nd May 20187:00 amRNSSuccessful Outcome of Study with FIT Biotech
30th Apr 20184:45 pmRNSHolding(s) in Company
17th Apr 20187:17 amEQSHardman & Co Research: Avacta (AVCT): Commendable rate of progress
16th Apr 20187:25 amRNSInterim Results
9th Apr 20182:58 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAvacta to Present at Investor Forum
29th Mar 20187:00 amRNSDirectorate Change
13th Mar 201812:02 pmRNSDirector/PDMR Shareholding
7th Mar 20184:35 pmRNSPrice Monitoring Extension
8th Feb 20187:00 amRNSSummary of Capital Markets Day
22nd Jan 20187:00 amRNSAvacta and OncoSec to Collaborate
18th Jan 201811:26 amRNSResult of Annual General Meeting
18th Jan 20187:00 amRNSAGM Business Update and Notice of Results
15th Jan 201810:58 amRNSHardmanResearch: Affimer Drug Conjugates a reality
15th Jan 20187:00 amRNSDrug Development Partnership with Glythera
8th Jan 20187:00 amRNSCapital Markets Day Notification
4th Jan 201811:04 amRNSPDMR Dealing and Issue of Equity
3rd Jan 20187:00 amRNSPresenting at the Biotech Showcase, San Francisco
18th Dec 20174:28 pmRNSIssue of Equity
4th Dec 201711:03 amRNSPosting of Annual Report and Notice of AGM
30th Nov 201710:57 amRNSIssue of Equity
15th Nov 20177:00 amRNSCovance to Present Affimer Data at Conference
14th Nov 20173:27 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSAvacta to Present at Investor Evening
13th Nov 20177:00 amRNSAvacta to present at PEGS Europe
24th Oct 20177:00 amRNSAffimers in Scientific Publications
19th Oct 20177:00 amRNSPrivate Shareholder Update Event
16th Oct 201710:42 amRNSHardman Res.: R&D accelerated to advance assets
12th Oct 20177:00 amRNSAvacta to Present at Shares Spotlight Evening
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.